摘要
醛甾酮(醛固酮)可损害血管内皮功能,抑制纤维蛋白溶解系统,加重血管壁的损伤和动脉粥样硬化病变的进展,诱导心肌的肥厚、纤维化和坏死。在心力衰竭治疗中应用血管紧张肽转换酶抑制药后可发生醛甾酮“逃逸”,使血管紧张肽转换酶抑制药的作用削弱。依普利酮是选择性的醛甾酮拮抗药。随机螺内酯评估研究表明在心力衰竭治疗中加用醛甾酮拮抗药可使总死亡率降低30%。
Aldosterone may impair vascular endothelial function, inhibit fibrinolysis, increase vascular wall tissue injury and development of atherosclerosis, and induce myocardial hypertrophy, fibrosis, and necrosis. ＂Escape＂ of aldosterone may occur in the treatment of heart failure with angiotensin-converting enzyme inhibitor, thus decreasing the effects of angiotensin-converting enzyme inhibitor. Eplerenone is a selective aldosterone antagonist. Randomized aldactone evaluation study （RALES） showed that adding aldosterone antagonist in the treatment of heart failure may decrease 30 % mortality of all causes.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第8期616-619,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
醛甾酮
醛甾酮拮抗药
心力衰竭
充血性
aldosterone
aldosterone antagonists
heart failure, congestive
